Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Success of new treatment halts international blood pressure drug trial

10.12.2004


An international trial comparing blood-pressure lowering treatments has been stopped early due to the significantly better performance of one of the treatments in the trial.



The 19,000 patient Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) has been comparing a new treatment strategy for hypertension against an old one, in order to discover which is better at preventing various cardiovascular events such as heart attacks and strokes.

The older treatment strategy based on the beta-blocker, atenolol and the thiazide diuretic, bendroflumethiazide was compared with a newer treatment strategy using the calcium channel blocker, amlodipine, and the angiotensin converting enzyme inhibitor, perindopril.


The blood pressure part of trial has been stopped because of cardiovascular benefits in favour of the newer calcium channel blocker plus angiotensin converting enzyme inhibitor treatment when compared with the beta-blocker, atenolol and the thiazide diuretic, bendroflumethiazide.

This announcement signals the end of the main clinical elements of the ASCOT trial, launched in 1997.

ASCOT study co-chairmen Björn Dahlöf, from the Sahlgrenska University Hospital, Östra, Sweden, and Peter Sever from Imperial College London, UK, comment: “This is excellent news for the many people who suffer from high blood pressure. Although at the moment we are unable to provide any definite figures on the effectiveness of the new treatments compared with the old, we have seen important significant differences.”

The Steering Committee of ASCOT accepted on 18 November the recommendation of its Data Safety Monitoring Board that the blood pressure arm of the trial should be stopped and the majority of patients have now been informed.

The complete results of the ASCOT trial will be made available when all data up to and including the last individual patient visit have been collected and analysed. Investigators and patients will be informed of the final results of ASCOT when these data become available. The results will be published in the scientific press.

Over the next few months all ASCOT patients will be seen for a final visit, when they will be given advice about future treatment of their hypertension.

Prior to their final visit, all patients are advised to stay on their existing drugs until they see their trial physician, to ensure their blood pressure remains controlled. The ASCOT trial doctors remind patients that sudden withdrawal of any treatment regimen could be harmful to them.

Of over 19,000 patients randomised to the two different blood pressure strategies, approximately 10,000 patients were also randomised to treatment with either atorvastatin or placebo in the ASCOT Lipid Lowering Arm (ASCOT-LLA). The ASCOT-LLA was stopped prematurely in October 2002, as a result of substantial benefits associated with statin use in the prevention of heart attacks and strokes.

The principal sponsor of ASCOT is Pfizer Inc, New York. Support has also been provided by Servier Research Group, Paris and Leo Laboratories, Copenhagen.

Tony Stephenson | alfa
Further information:
http://www.imperial.ac.uk

More articles from Health and Medicine:

nachricht Light beam replaces blood test during heart surgery
28.02.2017 | University of Central Florida

nachricht Cells adapt ultra-rapidly to zero gravity
28.02.2017 | Universität Zürich

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Scientists reach back in time to discover some of the most power-packed galaxies

28.02.2017 | Physics and Astronomy

Nano 'sandwich' offers unique properties

28.02.2017 | Materials Sciences

Light beam replaces blood test during heart surgery

28.02.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>